Thromboembolism after WATCHMANTM in a clopidogrel non-responder: A case for concern?

Published

Journal Article

© 2017 Wiley Periodicals, Inc. Atrial fibrillation (AF) is associated with an increased risk of stroke and thromboembolism (TE). The WATCHMANTM left atrial appendage (LAA) closure device is indicated to reduce the risk of TE from the LAA in patients with non-valvular AF. Here, we present a case of a patient with device-related thrombus who suffered a TE event two months after WATCHMANTM LAA closure and two weeks after switching from aspirin plus warfarin to aspirin plus clopidogrel therapy. Laboratory investigation identified the patient to be hypercoagulable and to be a non-responder to clopidogrel therapy. We discuss the potential role of platelet function testing to prevent device-related thrombi.

Full Text

Duke Authors

Cited Authors

  • Venkataraman, G; Bliden, KP; Tantry, US; Gurbel, PA

Published Date

  • July 1, 2018

Published In

Volume / Issue

  • 92 / 1

Start / End Page

  • 200 - 202

Electronic International Standard Serial Number (EISSN)

  • 1522-726X

International Standard Serial Number (ISSN)

  • 1522-1946

Digital Object Identifier (DOI)

  • 10.1002/ccd.27402

Citation Source

  • Scopus